Pembrolizumab Shows Modest Activity in Advanced Esophageal Cancer Pembrolizumab Shows Modest Activity in Advanced Esophageal Cancer

Pembrolizumab benefits a minority of heavily pretreated patients with advanced metastatic adenocarcinoma or squamous cell carcinoma of the esophagus, according to an open-label phase 2 trial.Reuters Health Information

Source: Medscape Medical News Headlines - December 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news